BlackBarn Capital Partners LP Raises Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

BlackBarn Capital Partners LP boosted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 3.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,125,000 shares of the company's stock after buying an additional 125,000 shares during the period. Roivant Sciences makes up about 2.7% of BlackBarn Capital Partners LP's investment portfolio, making the stock its biggest position. BlackBarn Capital Partners LP owned approximately 0.57% of Roivant Sciences worth $48,799,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Treasurer of the State of North Carolina raised its position in shares of Roivant Sciences by 0.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 187,047 shares of the company's stock valued at $2,213,000 after acquiring an additional 1,170 shares during the period. GAMMA Investing LLC raised its holdings in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares during the period. WINTON GROUP Ltd boosted its position in shares of Roivant Sciences by 1.5% during the fourth quarter. WINTON GROUP Ltd now owns 92,526 shares of the company's stock worth $1,095,000 after purchasing an additional 1,332 shares in the last quarter. Covestor Ltd grew its holdings in shares of Roivant Sciences by 7.5% in the 4th quarter. Covestor Ltd now owns 20,634 shares of the company's stock valued at $245,000 after buying an additional 1,444 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in shares of Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after buying an additional 1,507 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

Insider Activity

In related news, COO Eric Venker sold 434,478 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the completion of the transaction, the chief operating officer now directly owns 1,127,290 shares of the company's stock, valued at approximately $12,197,277.80. This represents a 27.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,395,541 shares of company stock worth $14,922,538 over the last ninety days. Insiders own 7.90% of the company's stock.

Roivant Sciences Price Performance

ROIV stock traded up $0.01 during trading hours on Friday, reaching $11.01. 8,016,575 shares of the stock were exchanged, compared to its average volume of 5,462,047. The company has a market cap of $7.86 billion, a price-to-earnings ratio of -73.40 and a beta of 1.25. The firm's 50-day moving average is $10.34 and its 200-day moving average is $11.15. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, equities research analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

ROIV has been the topic of several recent analyst reports. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.